Notable Tuesday Option Activity: WBD, C, JBIO

Citigroup options traded 51,535 contracts today—about 5.2 million underlying shares and roughly 45.7% of C’s one‑month average daily volume (11.3 million shares)—with outsized interest in the $115 call expiring Jan. 16, 2026 (3,337 contracts, ~333,700 shares). Jade Biosciences saw 1,007 option contracts (~100,700 underlying shares), equal to about 43.3% of its one‑month average daily volume (232,710 shares), concentrated in the $12.50 call expiring Nov. 21, 2025 (1,004 contracts, ~100,400 shares). The scale and concentration of these long‑dated call flows represent meaningful directional positioning or hedging activity that is large relative to typical equity turnover and could amplify near‑term stock price moves in both names.

Analysis

Citigroup saw options trading volume of 51,535 contracts today, equivalent to roughly 5.2 million underlying shares or about 45.7% of C's one‑month average daily equity volume of 11.3 million shares. Activity was concentrated in the $115 call expiring January 16, 2026, where 3,337 contracts traded (~333,700 underlying shares), signaling concentrated long‑dated interest in that strike.

Jade Biosciences recorded 1,007 option contracts (~100,700 underlying shares), representing about 43.3% of its one‑month average daily volume of 232,710 shares, with 1,004 contracts in the $12.50 call expiring November 21, 2025 (~100,400 shares). The concentration in a single strike and expiry for JBIO is large relative to the stock's typical turnover and therefore has greater potential to move the underlying.

Concentration in long‑dated calls across both names suggests sizeable directional positioning or hedging that can amplify near‑term stock moves and lift implied volatility; accompanying signals show neutral sentiment and a modest market‑impact score (0.25). The article cautions that volume alone does not identify whether trades are opening purchases, closing sales, or complex spreads, so investors should look for confirming price action and open‑interest changes before inferring sustained bullishness.

Key Decisions for Investors

• Monitor open interest and intraday price reaction for C's $115 Jan‑16‑2026 and JBIO's $12.50 Nov‑21‑2025 strikes to differentiate new bullish buying from spreads or position rolls
• For JBIO, avoid initiating large directional equity positions ahead of options‑driven moves given the contracts represent ~43% of one‑month average volume and could produce outsized volatility
• For C, consider using hedges or defined‑risk option structures (for example call spreads) rather than large outright equity exposure given the sizeable but not overwhelming options flow relative to its average daily volume